Cellectar Biosciences (NASDAQ:CLRB) Upgraded by Brookline Capital Markets to Strong-Buy Rating

Posted by George Bondi on Jul 14th, 2026

Brookline Capital Markets upgraded shares of Cellectar Biosciences (NASDAQ:CLRB – Free Report) to a strong-buy rating in a research report released on Sunday,Zacks.com reports. Brookline Capital Markets also issued estimates for Cellectar Biosciences’ Q1 2027 earnings at ($0.50) EPS, Q2 2027 earnings at ($0.68) EPS, Q3 2027 earnings at ($0.66) EPS, Q4 2027 earnings at ($0.50) EPS and FY2027 earnings at ($2.34) EPS.

CLRB has been the subject of a number of other research reports. LADENBURG THALM/SH SH started coverage on shares of Cellectar Biosciences in a research report on Friday, May 15th. They set a “buy” rating for the company. Roth Capital reissued a “buy” rating and issued a $11.00 target price on shares of Cellectar Biosciences in a research report on Tuesday, May 5th. Wall Street Zen raised shares of Cellectar Biosciences to a “hold” rating in a research report on Saturday, June 20th. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Cellectar Biosciences in a report on Monday, April 20th. One investment analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $11.00.

Get Our Latest Research Report on CLRB

Cellectar Biosciences Price Performance

Shares of Cellectar Biosciences stock opened at $2.63 on Friday. Cellectar Biosciences has a 1-year low of $2.20 and a 1-year high of $6.52. The business has a 50-day moving average of $2.81 and a 200-day moving average of $2.99. The company has a market capitalization of $21.01 million, a PE ratio of -0.39 and a beta of 0.55.

Cellectar Biosciences (NASDAQ:CLRB – Get Free Report) last issued its quarterly earnings results on Thursday, May 14th. The biopharmaceutical company reported ($1.33) EPS for the quarter, beating analysts’ consensus estimates of ($1.88) by $0.55. On average, equities analysts expect that Cellectar Biosciences will post -2.34 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Cellectar Biosciences

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Bank of America Corp DE grew its holdings in shares of Cellectar Biosciences by 25.3% during the fourth quarter. Bank of America Corp DE now owns 206,783 shares of the biopharmaceutical company’s stock valued at $62,000 after purchasing an additional 41,704 shares during the last quarter. Dimensional Fund Advisors LP acquired a new position in Cellectar Biosciences during the 3rd quarter valued at approximately $73,000. Citadel Advisors LLC acquired a new position in Cellectar Biosciences during the 3rd quarter valued at approximately $104,000. Sequoia Financial Advisors LLC grew its stake in Cellectar Biosciences by 135.1% during the 4th quarter. Sequoia Financial Advisors LLC now owns 25,350 shares of the biopharmaceutical company’s stock worth $75,000 after buying an additional 14,567 shares during the last quarter. Finally, Geode Capital Management LLC increased its position in Cellectar Biosciences by 15.0% in the fourth quarter. Geode Capital Management LLC now owns 28,636 shares of the biopharmaceutical company’s stock worth $84,000 after buying an additional 3,744 shares during the period. 16.41% of the stock is currently owned by institutional investors and hedge funds.

About Cellectar Biosciences

(Get Free Report)

Cellectar Biosciences, Inc is a clinical‐stage biopharmaceutical company focused on the development of targeted cancer therapies and imaging agents. The company’s proprietary phospholipid drug conjugate (PDC) technology platform is designed to selectively deliver therapeutic and diagnostic payloads to malignant cells while sparing healthy tissue. Through its PDC approach, Cellectar aims to improve the efficacy and safety profile of traditional treatments like chemotherapy and radiotherapy.

Its lead therapeutic candidate, CLR 131, is a radioisotope‐labeled PDC being evaluated in Phase II clinical trials for relapsed or refractory B‐cell malignancies, including multiple myeloma and non‐Hodgkin lymphoma.